Table 2 Cytotoxicity EC100 values (µM), effective anti-inflammatory concentrations (µM) and TNF-α (µg/mL), INF-γ (µg/mL) and IL-1β (µg/mL) levels of the isolated compounds
Sample | Cytotoxicity EC100 (µM) ± SD | Effective anti-inflammatory concentrationS (µM) ± SD | TNF-α (µg/mL) ± SD | INF-γ (µg/mL) ± SD | IL-1β (µg/mL) ± SD |
|---|---|---|---|---|---|
Compound 1 Alternariol monomethyl ether | 77.0 ± 6.0 | 1.0 ± 0.3 | 0.25 ± 0.02 | 0.27 ± 0.06 | 0.30 ± 0.03 |
Compound 2 3’-Hydroxyalternariol monomethyl ether | 64.0 ± 3.0 | 0.9 ± 0.2 | 0.31 ± 0.09 | 0.20 ± 0.07 | 0.18 ± 0.004 |
Compound 3 Alternariol | 75.0 ± 5.0 | 2.0 ± 0.03 | 0.27 ± 0.08 | 0.34 ± 0.02 | 0.24 ± 0.009 |
Compound 4 α-Acetylorcinol | 20.0 ± 2.0 | 3.7 ± 0.06 | 0.37 ± 0.009 | 0.39 ± 0.01 | 0.21 ± 0.08 |
Mixture of tenuazonic acid (compound 5) and allo-tenuazonic acid (compound 6) | 8.0 ± 1.0 | 3.8 ± 0.1 | 0.34 ± 0.007 | 0.34 ± 0.05 | 0.23 ± 0.02 |
Piroxicam | 53.0 ± 8.0 | 3.0 ± 0.7 | 0.57 ± 0.01 | 1.36 ± 0.30 | 0.66 ± 0.10 |
LPS-stimulated WBCs | - | - | 2.36 ± 0.85 | 5.69 ± 1.02 | 2.69 ± 0.58 |
Normal cells (control) | - | - | 0.79 ± 0.03 | 2.51 ± 0.58 | 1.16 ± 0.085 |